Electronic Health Systems Pioneer Carla Balch Joins Aranscia’s Executive Leadership Team
Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, announced that it has acquired Spesana and its best-in-class suite of patient navigation, clinical collaboration, and oncology clinical decision support utilities. Spesana’s Founder and CEO, Carla Balch, a leading pioneer in healthcare and oncology information systems, will serve as Executive Director across all Aranscia software solutions, including oversight of Spesana’s continued commercial and technical expansion.
Health Technology Insights: RevenueWell Partners With Mila Health to Launch Next-Gen AI-Powered Assistant
Spesana, founded in 2019, has developed a healthcare platform that increases the velocity, efficiency, and utility of innovative precision medicine programs. The Company’s patient navigation, prior authorization, clinical trial collaboration, and diagnostic workflow solutions are in use across over 140 clinical sites, and its blue-chip customer base includes leading payers, multi-site provider and oncology organizations, and diagnostic laboratories. Spesana clients have reported a 60% improvement in the use of appropriate precision medicine diagnostics by eliminating clinical overhead and process ambiguity with Spesana’s intelligent platform utilities.
Spesana will join the Aranscia portfolio of companies, each of which shares a synergistic mission of solving the tactical gaps in clinical workflows and democratizing access to the promises of precision care. This portfolio includes 2bPrecise, the award-winning platform for lab-agnostic, EMR-integrated solutions that deliver unparalleled speed-to-value in precision care; YouScript, a widely recognized leader in actionable, real-time personalized medication risk management and pharmacogenomics (PGx) insights; and AccessDx Laboratory, a CLIA-certified, CAP-accredited, and NYCQ molecular diagnostic laboratory with specialist expertise in PGx and other personalized diagnostics.
Health Technology Insights: Northwell Health Commits $1.3Million to Fund Employee Health Innovations
“We warmly welcome the entire Spesana team and platform to the Aranscia family of companies,” said Joe Spinelli, Chief Strategy Officer, Aranscia. “Spesana and Aranscia have a clear and shared mission of developing and implementing best-in-class utilities that improve clinical, financial, and operational workflows for providers and the patients they serve. Carla’s experience as a proven operator, builder, and ally to clinical partners makes her a perfect fit to lead Aranscia’s software efforts as we assert our unified focus on positively impacting outcomes at the point of care.”
Ms. Balch was previously President and CEO of Altos Solutions, which developed the first web-based oncology medical records company, and was subsequently acquired by Flatiron Health. Prior to Spesana, Ms. Balch also served as President of Nantcare, an oncology technology and clinical trials company, and as CEO of Inteliquet (acquired by IQVIA), an innovative clinical trial matching solution. Ms. Balch serves on the Healthcare Counsel of the Federal Reserve Bank of St. Louis.
“We built Spesana to unify fragmented healthcare workflows, and joining Aranscia allows us to realize that mission at scale,” said Carla Balch, CEO of Spesana. “Our teams share a commitment to modernizing the clinician experience by eliminating technology silos and delivering a seamless, integrated, HIPAA-compliant platform across all specialties and sites of care. Together, and in collaboration with the clinical partners we serve, we will continue to deliver solutions that improve both patient outcomes and provider experiences and help to enable more connected, efficient, and intelligent healthcare.”
Health Technology Insights: OMNY Health Adds 300+ Health Measures for Disease Research
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
